National Health Research Institutes (Taiwan) and Hi-Q Marine Biotech joined research cooperation
National Health Research Institutes (Taiwan) and Hi-Q Marine Biotech joined research cooperation to explore the mechanism and effects of Oligo fucoidan in inhibiting liver cancer and non-alcoholic fatty liver disease. The research results were published in the international journal on December 21, 2020 (Clinical and Translation Medicine)
This research investigated the effects and mechanisms of low molecular weight fucoidan (i.e. oligo?fucoidan [OF]) preventing hepatocarcinogenesis. This research provided evidence that Oligo Fucoidan exhibits the anti? Hepatocellular carcinoma, anti?steatosis, and anti?fibrosis effect for liver in zebrafish models, and the anti?cancer potential of Oligo Fucoidan attributed to the binding to ASGR and activation of STAT3/HNF4A signaling. Oligo Fucoidan might be potentially valuable for the management of Hepatocellular carcinoma.
Low molecular weight fucoidan inhibits hepatocarcinogenesis and nonalcoholic fatty liver disease in zebrafish via ASGR/STAT3/HNF4A signaling
First published: 21 December 2020
Mechanism of Oligo fucoidan in inhibiting liver cancer and non-alcoholic fatty liver disease.
Chiou-Hwa Yuh, Ph.D., the corresponding author with Camy Wang, General Manager of Hi-Q Marine Biotec